Theravance Biopharma, Inc. Annual Deferred Income Tax Expense (Benefit) in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Theravance Biopharma, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2012 to 2023.
  • Theravance Biopharma, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$513K.
  • Theravance Biopharma, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $3.21M.
  • Theravance Biopharma, Inc. annual Deferred Income Tax Expense (Benefit) for 2017 was $0.000.
  • Theravance Biopharma, Inc. annual Deferred Income Tax Expense (Benefit) for 2016 was $0.000.
Deferred Income Tax Expense (Benefit), Annual (USD)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $3.21M Jan 1, 2023 Dec 31, 2023 10-K 2024-03-01
2017 $0 $0 Jan 1, 2017 Dec 31, 2017 10-K 2018-02-28
2016 $0 $0 Jan 1, 2016 Dec 31, 2016 10-K 2018-02-28
2015 $0 $0 Jan 1, 2015 Dec 31, 2015 10-K 2018-02-28
2014 $0 $0 Jan 1, 2014 Dec 31, 2014 10-K 2017-03-01
2013 $0 $0 Jan 1, 2013 Dec 31, 2013 10-K 2016-03-11
2012 $0 Jan 1, 2012 Dec 31, 2012 10-K 2015-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.